Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy

Pharmacogenomics Journal

Volumn 12, Issue 6, 2012, Pages 489-498

  Palei, A C T ^a   Sandrim, V C ^b   Amaral, L M ^c   MacHado, J S R ^c   Cavalli, R C ^c   Lacchini, R ^c   Duarte, G ^c   Tanus Santos, J E ^c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Santa Casa of Belo Horizonte   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antihypertensive therapy; gestational hypertension; MMP 9; pharmacogenetics; polymorphism; preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT; GELATINASE B; HYDRALAZINE; METHYLDOPA; NIFEDIPINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ALLELE; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MATRIX METALLOPROTEINASE 9; PRE-ECLAMPSIA; PREGNANCY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84870063498     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.31     Document Type: Article

References (35)

1. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59: 61-78.
2. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005; 45: 258-263.
3. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46: 1243-1249.
4. Leik CE, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension 2004; 44: 72-77.
5. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
6. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 2001; 20: 185-194.
7. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008; 41: 875-880.
8. Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and-2 levels in gestational hypertension. Am J Hypertens 2005; 18: 325-329.
9. Kolben M, Lopens A, Blaser J, Ulm K, Schmitt M, Schneider KT et al. Proteases and their inhibitors are indicative in gestational disease. Eur J Obstet Gynecol Reprod Biol 1996; 68: 59-65.
10. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 2009; 23: 88-92.
11. Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H et al. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003; 24: 53-64.
12. Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T, Yagel S. Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. Am J Obstet Gynecol 1994; 171: 832-838.
13. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152: 189-205.
14. Jeyabalan A, Novak J, Doty KD, Matthews J, Fisher MC, Kerchner LJ et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 2007; 148: 189-197.
15. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 2006; 8: 1-20.
16. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
17. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
18. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30: 2612-2616.
19. Shimajiri S, Arima N, Tanimoto A, Murata Y, Hamada T, Wang KY et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999; 455: 70-74.
20. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Tanus-Santos JE. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 2009; 9: 265-273.
21. Coolman M, de Maat M, Van Heerde WL, Felida L, Schoormans S, Steegers EA et al. Matrix metalloproteinase-9 gene-1562C/T polymorphism mitigates preeclampsia. Placenta 2007; 28: 709-713.
22. Palei AC, Sandrim VC, Duarte G, Cavalli RC, Gerlach RF, Tanus-Santos JE. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta 2010; 411: 874-877.
23. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
24. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 2006; 365: 183-187.
25. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva Jr WA, Tanus-Santos JE. Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 2008; 46: 57-63.
26. Lacchini R, Jacob-Ferreira AL, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S et al. Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 2010; 411: 1940-1944.
27. Lacchini R, Metzger IF, Luizon M, Ishizawa M, Tanus-Santos JE. Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol 2010; 29: 649-655.
28. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenom J 2010; 10: 40-45.
29. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens 2003; 21: 1627-1630.
30. Chappell S, Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond) 2006; 110: 443-458.
31. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51: 960-969.
32. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006; 47: 117-122.
33. Zervoudaki A, Economou E, Pitsavos C, Vasiliadou K, Aggeli C, Tsioufis K et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and-9 in essential hypertension. Am J Hypertens 2004; 17: 273-276.
34. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119-124.
35. Marcal DM, Rizzi E, Martins-Oliveira A, Ceron CS, Guimaraes DA, Gerlach RF et al. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 35-44.